• ChemFaces is a professional high-purity natural products manufacturer.
  • Product Intended Use
  • 1. Reference standards
  • 2. Pharmacological research
  • 3. Inhibitors
  • Home
  • Natural Products
  • Bioactive
  • Screening Libraries
  • Hot Products
  • Plant Catalog
  • Customer Support
  • Product Use Citation
  • About Us
  • Contact Us
  • Natural Products
    CAS No. 33419-42-0 Price $50 / 20mg
    Catalog No.CFN89061Purity>=98%
    Molecular Weight588.56Type of CompoundLignans
    FormulaC29H32O13Physical DescriptionPowder
    Download     COA    MSDSSimilar structuralComparison (Web)
    Citing Use of our Products
    How to Order
    Orders via your E-mail:

    1. Product number / Name / CAS No.
    2. Delivery address
    3. Ordering/billing address
    4. Contact information
    Sent to Email: info@chemfaces.com
    Contact Us
    Order & Inquiry & Tech Support

    Tel: (0086)-27-84237683
    Fax: (0086)-27-84254680
    E-mail: manager@chemfaces.com
    Address: No. 83, CheCheng Rd., WETDZ, Wuhan, Hubei 430056, PRC
    Delivery time
    Delivery & Payment method

    1. Usually delivery time: Next day delivery by 9:00 a.m. Order now

    2. We accept: Wire transfer & Credit card & Paypal & Western Union
    * Packaging according to customer requirements(5mg, 10mg, 20mg and more). We shipped via FedEx, DHL, UPS, EMS and others courier.
    According to end customer requirements, ChemFaces provide solvent format. This solvent format of product intended use: Signaling Inhibitors, Biological activities or Pharmacological activities.
    Size /Price /Stock 10 mM * 1 mL in DMSO / $23.4 / In-stock
    Other Packaging *Packaging according to customer requirements(100uL/well, 200uL/well and more), and Container use Storage Tube With Screw Cap
    Our products had been exported to the following research institutions and universities, And still growing.
  • University of Bordeaux (France)
  • University of Toulouse (France)
  • Istanbul University (Turkey)
  • Massachusetts General Hospital (USA)
  • Sri Sai Aditya Institute of Pha... (India)
  • Universidad Veracuzana (Mexico)
  • Universiti Sains Malaysia (Malaysia)
  • Kazusa DNA Research Institute (Japan)
  • Uniwersytet Medyczny w ?odzi (Poland)
  • Stanford University (USA)
  • Pennsylvania State University (USA)
  • More...
  • Package
    Featured Products
    Kushenol X

    Catalog No: CFN92390
    CAS No: 254886-77-6
    Price: $568/5mg
    Sanggenone K

    Catalog No: CFN92416
    CAS No: 86450-77-3
    Price: $533/5mg

    Catalog No: CFN99762
    CAS No: 957-66-4
    Price: $238/5mg

    Catalog No: CFN97048
    CAS No: 61276-17-3
    Price: $60/20mg

    Catalog No: CFN98307
    CAS No: 264234-05-1
    Price: $438/10mg
    Platycoside M1

    Catalog No: CFN92267
    CAS No: 917482-67-8
    Price: $468/5mg
    Cyanidin-3-O-glucoside chloride

    Catalog No: CFN99740
    CAS No: 7084-24-4
    Price: $118/20mg
    Related Screening Libraries
    Size /Price /Stock 10 mM * 100 uL in DMSO / Inquiry / In-stock
    10 mM * 1 mL in DMSO / Inquiry / In-stock
    Related Libraries
  • Anticancer Compound Library
  • Inhibitors Compound Library
  • Pro-apoptotic Compound Library
  • Antileukaemic Compound Library
  • Lignans Compound Library
  • Topoisomerase Inhibitor Library
  • Caspase Inhibitor Library
  • Biological Activity
    Description: Etoposide is a chemotherapy medication used for the treatments of a number of types of cancer. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA, it induces apoptosis in MCF-7 breast cancer cells.
    Targets: Topoisomerase | Caspase
    In vitro:
    Cancer Res. 2001 Jan 1;61(1):348-54.
    Reconstitution of caspase 3 sensitizes MCF-7 breast cancer cells to doxorubicin- and etoposide-induced apoptosis.[Pubmed: 11196185]
    MCF-7, a breast cancer-derived cell line, is deficient of caspase 3 and relatively insensitive to many chemotherapeutic agents.
    To study the association of caspase 3 deficiency and chemotherapeutic resistance, we reconstituted caspase 3 in MCF-7 cells and characterized their apoptotic response to doxorubicin and Etoposide. Western blots demonstrated that caspase 3 was constitutively expressed in the reconstituted MCF-7 cells. Both morphological observation and survival assays showed that caspase 3 reconstitution significantly sensitized MCF-7 cells to both drugs. Remarkably increased activation of caspases 3, 6, and 7, cleavage of cellular death substrates, and DNA fragmentation were detected in the reconstituted MCF-7 cells after drug treatment.
    Together, these data demonstrated a specific role for caspase 3 in chemotherapy-induced apoptosis and in activation of caspases 6 and 7. Our results also suggest that caspase 3 deficiency may contribute to chemotherapeutic resistance in breast cancer.
    In vivo:
    Endocr Relat Cancer. 2005 Sep;12(3):657-66.
    Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial.[Pubmed: 16172198]

    To investigate the activity of Etoposide, doxorubicin, and cisplatin plus mitotane in the management of advanced adrenocortical carcinoma (ACC) patients, 72 patients with measurable disease not amenable to radical surgery were enrolled in a prospective, multicenter phase II trial. EDP schedule (Etoposide 100 mg/m(2) on days 5-7, doxorubicin 20 mg/m(2) on days 1 and 8, and cisplatin 40 mg/m(2) on days 1 and 9) was administered intravenously every 4 weeks. Concomitantly, patients were given up to 4 g/day of oral mitotane. Five patients achieved a complete response and 30 a partial response, for an overall response rate of 48.6% (95% CI: 37.1-60.3). Median time to progression in responding patients was 18 months. The EDP regimen was well tolerated, leukopenia being the dose limiting toxicity. One toxic related death due to septic shock, however, was registered. Radical surgical resection of residual disease after chemotherapy was performed in 10 patients. The overall survival of patients attaining a disease free status (clinical complete responders+radically resected) was significantly higher than that of patients with partial response or no response (P<0.002). Androgen secretion was associated with long survival, while glucocorticoid secretion was associated with poor prognosis both in univariate and multivariate analysis.
    In conclusion, EDP plus mitotane is an active and manageable combination scheme for ACC patients. Surgical resection of residual disease subsequent to chemotherapy leads to a more favourable outcome. The natural history of the disease is significantly influenced by the secretory status of the tumor.
    J Clin Oncol. 2000 Mar;18(6):1173-80.
    Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients.[Pubmed: 10715285 ]
    To evaluate the efficacy and toxicity of sequential, dose-intensified chemotherapy with paclitaxel/ifosfamide and carboplatin/Etoposide administered plus peripheral blood-derived stem-cell (PBSC) support for patients with germ cell tumors (GCT) who have unfavorable prognostic features in response to conventional-dose salvage programs. Carboplatin was dose escalated by target area under the curve (AUC; in [milligrams per milliliter] x minutes) among patient cohorts, and pharmacokinetic studies were performed for comparison.
    Thirty-seven previously treated patients who had cisplatin-resistant GCT and unfavorable prognostic features for response to conventional-dose salvage therapy were treated. Two cycles of paclitaxel 200 mg/m(2) plus ifosfamide 6 g/m(2) were given 2 weeks apart with leukapheresis, followed by three cycles of carboplatin plus Etoposide given 14 to 21 days apart with reinfusion of PBSCs. The dose of Etoposide was 1, 200 mg/m(2), and the carboplatin target AUC ranged among cohorts from 12 to 32 (mg/mL) x min. Pharmacokinetic studies of carboplatin were performed for comparison of target to measured AUC. Twenty-one patients (57%) achieved a complete response and an additional two patients (5%) achieved a partial response with normal tumor markers; therefore, 23 (62%) achieved a favorable response. Eight patients relapsed, and 15 (41%) of the favorable responses remained durable at a median follow-up of 30 months. Myelosuppression was the major toxicity; 58% of carboplatin/Etoposide cycles were associated with hospitalization for nadir fever. The AUC of carboplatin measured in serum was lower than the target AUC; this may be related to underestimation of the glomerular filtration rate used in the dosing formula.
    Dose-intense therapy with sequential, accelerated chemotherapy of paclitaxel/ifosfamide and carboplatin/Etoposide administered with PBSC support was relatively well tolerated. The durable complete response proportion was substantial in patients with unfavorable prognostic features for achieving durable complete response to conventional-dose salvage programs. Optimal dosing of carboplatin in the high-dose setting warrants further investigation.
    Leuk Lymphoma. 1994 Sep;15(1-2):127-30.
    Idarubicin, high-dose cytarabine and etoposide for remission induction in therapy-related acute myeloid leukemia[Pubmed: 7858489 ]

    Five patients with therapy-related acute myeloid leukemia received combination induction chemotherapy with idarubicin, high-dose cytarabine, and Etoposide. Complete remission was achieved in all patients with a single course of therapy. Treatment-related toxicity included nausea, vomiting, mucositis, diarrhea, and liver and kidney function abnormalities, and was low in all patients. There were no deaths during induction therapy.
    We conclude that this combination is well-tolerated in induction of remission in secondary acute myeloid leukemia, and warrants further assessment because of a very good complete remission rate.
    Etoposide Description
    Source: The herbs of Dysosma versipellis.
    Solvent: Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
    Storage: Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

    Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

    Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

    After receiving: The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
    Recent ChemFaces New Products and Compounds

    Catalog No: CFN96416
    CAS No: 13060-14-5
    Price: $398/5mg
    Licoricesaponin H2

    Catalog No: CFN95173
    CAS No: 118441-85-3
    Price: $218/10mg
    Semilicoisoflavone B

    Catalog No: CFN90818
    CAS No: 129280-33-7
    Price: $318/5mg
    Specioside B

    Catalog No: CFN95165
    CAS No: 126589-95-5
    Price: $368/5mg

    Catalog No: CFN95213
    CAS No: 119240-82-3
    Price: $413/5mg
    Ganoderic acid D

    Catalog No: CFN90292
    CAS No: 108340-60-9
    Price: $368/10mg
    Kaempferol 7-O-rhamnoside

    Catalog No: CFN96224
    CAS No: 20196-89-8
    Price: $338/5mg

    Catalog No: CFN95180
    CAS No: 27062-01-7
    Price: $318/10mg
    Recently, ChemFaces products have been cited in many studies from excellent and top scientific journals

    Cell. 2018 Jan 11;172(1-2):249-261.e12.
    doi: 10.1016/j.cell.2017.12.019.

    PMID: 29328914

    Cell Metab. 2020 Mar 3;31(3):534-548.e5.
    doi: 10.1016/j.cmet.2020.01.002.

    PMID: 32004475

    Mol Cell. 2017 Nov 16;68(4):673-685.e6.
    doi: 10.1016/j.molcel.2017.10.022.

    PMID: 29149595

    ACS Nano. 2018 Apr 24;12(4): 3385-3396.
    doi: 10.1021/acsnano.7b08969.

    PMID: 29553709

    Nature Plants. 2016 Dec 22;3: 16206.
    doi: 10.1038/nplants.2016.205.

    PMID: 28005066

    Sci Adv. 2018 Oct 24;4(10): eaat6994.
    doi: 10.1126/sciadv.aat6994.

    PMID: 30417089
    Calculate Dilution Ratios(Only for Reference)
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 1.6991 mL 8.4953 mL 16.9906 mL 33.9812 mL 42.4766 mL
    5 mM 0.3398 mL 1.6991 mL 3.3981 mL 6.7962 mL 8.4953 mL
    10 mM 0.1699 mL 0.8495 mL 1.6991 mL 3.3981 mL 4.2477 mL
    50 mM 0.034 mL 0.1699 mL 0.3398 mL 0.6796 mL 0.8495 mL
    100 mM 0.017 mL 0.085 mL 0.1699 mL 0.3398 mL 0.4248 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
    Kinase Assay:
    Eur J Cancer. 1998 Sep;34(10):1514-21.
    Etoposide: four decades of development of a topoisomerase II inhibitor.[Pubmed: 9893622]
    Podophyllin-containing materials have been used as folk medicines for centuries. In the 1950s, scientists began a search to identify a more effective podophyllotoxin derivative. These efforts eventually resulted in the development of a new class of antineoplastic agents which target the DNA unwinding enzyme, topoisomerase II.
    The history of the development of one of the first identified topoisomerase II inhibitors, Etoposide, is reviewed in this paper. Critical developments in Etoposide's mechanism of action, pharmacology and administration schedule are summarised. The clinical benefits of the recently marketed Etoposide prodrug, Etoposide phosphate (Etopophos) are also detailed. The current status of other clinically approved anticancer agents which target topoisomerase II is briefly reviewed.